These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26657294)

  • 1. Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer.
    De Marchi T; Timmermans AM; Smid M; Look MP; Stingl C; Opdam M; Linn SC; Sweep FC; Span PN; Kliffen M; van Deurzen CH; Luider TM; Foekens JA; Martens JW; Umar A
    Oncotarget; 2016 Jan; 7(3):3098-110. PubMed ID: 26657294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera.
    De Marchi T; Kuhn E; Dekker LJ; Stingl C; Braakman RB; Opdam M; Linn SC; Sweep FC; Span PN; Luider TM; Foekens JA; Martens JW; Carr SA; Umar A
    J Proteome Res; 2016 Apr; 15(4):1230-42. PubMed ID: 26958999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer.
    De Marchi T; Liu NQ; Stingl C; Timmermans MA; Smid M; Look MP; Tjoa M; Braakman RB; Opdam M; Linn SC; Sweep FC; Span PN; Kliffen M; Luider TM; Foekens JA; Martens JW; Umar A
    Mol Oncol; 2016 Jan; 10(1):24-39. PubMed ID: 26285647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
    Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer.
    Ignatov A; Ignatov T; Weissenborn C; Eggemann H; Bischoff J; Semczuk A; Roessner A; Costa SD; Kalinski T
    Breast Cancer Res Treat; 2011 Jul; 128(2):457-66. PubMed ID: 21607586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer.
    Meijer D; Sieuwerts AM; Look MP; van Agthoven T; Foekens JA; Dorssers LC
    Endocr Relat Cancer; 2008 Mar; 15(1):101-11. PubMed ID: 18310279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of 14-3-3ζ expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.
    Thistle JE; Hellberg Y; Mortensen K; Hamilton-Dutoit S; Kjærsgaard A; Cronin-Fenton D; Sørensen HT; Lash TL
    Breast Cancer Res Treat; 2017 Oct; 165(3):633-643. PubMed ID: 28643021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.
    Dowsett M; Houghton J; Iden C; Salter J; Farndon J; A'Hern R; Sainsbury R; Baum M
    Ann Oncol; 2006 May; 17(5):818-26. PubMed ID: 16497822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
    Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
    JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
    Miller TW; Balko JM; Ghazoui Z; Dunbier A; Anderson H; Dowsett M; González-Angulo AM; Mills GB; Miller WR; Wu H; Shyr Y; Arteaga CL
    Clin Cancer Res; 2011 Apr; 17(7):2024-34. PubMed ID: 21346144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
    Meijer D; Jansen MP; Look MP; Ruigrok-Ritstier K; van Staveren IL; Sieuwerts AM; van Agthoven T; Foekens JA; Dorssers LC; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):253-60. PubMed ID: 18299979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.
    Ahern TP; Cronin-Fenton DP; Lash TL; Sørensen HT; Ording AG; Hamilton-Dutoit SJ; Hellberg Y
    Acta Oncol; 2016 Jun; 55(6):734-41. PubMed ID: 27056567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors predictive of response to hormone therapy in breast cancer.
    Rastelli F; Crispino S
    Tumori; 2008; 94(3):370-83. PubMed ID: 18705406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
    Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study.
    Cronin-Fenton DP; Hellberg Y; Lauridsen KL; Ahern TP; Garne JP; Rosenberg C; Silliman RA; Sørensen HT; Lash TL; Hamilton-Dutoit S
    Acta Oncol; 2012 Feb; 51(2):254-61. PubMed ID: 22129357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer.
    Planas-Silva MD; Bruggeman RD; Grenko RT; Smith JS
    Exp Mol Pathol; 2007 Feb; 82(1):85-90. PubMed ID: 17046747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study.
    Hjorth CF; Nielsen AS; Sørensen HT; Lash TL; Damkier P; Hamilton-Dutoit S; Cronin-Fenton D
    Acta Oncol; 2019 Feb; 58(2):168-174. PubMed ID: 30458661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.
    Jansen MP; Reijm EA; Sieuwerts AM; Ruigrok-Ritstier K; Look MP; Rodríguez-González FG; Heine AA; Martens JW; Sleijfer S; Foekens JA; Berns EM
    Breast Cancer Res Treat; 2012 Jun; 133(3):937-47. PubMed ID: 22094936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.